<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565367</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-39845</org_study_id>
    <secondary_id>NCI-2018-01122</secondary_id>
    <secondary_id>IRB-39845</secondary_id>
    <secondary_id>BRN0036</secondary_id>
    <nct_id>NCT03565367</nct_id>
  </id_info>
  <brief_title>Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors</brief_title>
  <official_title>A Pilot Study to Assess Lactate and Bicarbonate Detection Within Malignant Brain Tumors Using [1-13C]-Pyruvate DNP Magnetic Resonance Spectroscopy (MRS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel M. Spielman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well hyperpolarized carbon C 13 pyruvate magnetic
      resonance imaging works in detecting lactate and bicarbonate in participants with central
      nervous system tumors. Hyperpolarized carbon C 13 pyruvate magnetic resonance imaging may be
      used to measure the metabolic state of malignant brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the safety of intravenous (IV) injection of hyperpolarized carbon C 13 pyruvate
      (hyperpolarized [1-13C] pyruvate) for magnetic resonance imaging (MRI).

      II. To assess the frequency and sensitivity with which lactate and bicarbonate signals can be
      detected in malignant brain tumors after IV injection of hyperpolarized [1-13C] pyruvate.

      OUTLINE:

      Participants undergo MRI over 45 minutes at baseline. Participants then receive
      hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants
      undergo magnetic resonance spectroscopic imaging (MRSI) over 3 minutes and MRI over 10
      minutes (participants may receive gadolinium at the discretion of the protocol director).

      After completion of study, participants are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Logistics
  </why_stopped>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">January 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 2 or Higher Toxicities</measure>
    <time_frame>Day 4</time_frame>
    <description>The measurement of this drug will be Grade 2 or higher related adverse events (except for asymptomatic lab increases)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate and Bicarbonate Production in Tumor and Normal Brain Tissue</measure>
    <time_frame>Day 4</time_frame>
    <description>The outcome is defined as the frequency of hyperpolarized carbon C 13 pyruvate magnetic resonance signal detection above background noise level of both lactate and bicarbonate in all tumors screened.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Malignant Central Nervous System Neoplasm</condition>
  <condition>Metastatic Malignant Neoplasm in the Central Nervous System</condition>
  <arm_group>
    <arm_group_label>Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <description>gadolinium enhanced MRI</description>
    <arm_group_label>Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)</arm_group_label>
    <other_name>Gd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized Carbon C 13 Pyruvate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)</arm_group_label>
    <other_name>Hyperpolarized 13C-Pyruvate</other_name>
    <other_name>Hyperpolarized Pyruvate (13C)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI</description>
    <arm_group_label>Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Spectroscopic Imaging</intervention_name>
    <description>Undergo MRSI</description>
    <arm_group_label>Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)</arm_group_label>
    <other_name>1H- Nuclear Magnetic Resonance Spectroscopic Imaging</other_name>
    <other_name>1H-nuclear magnetic resonance spectroscopic imaging</other_name>
    <other_name>Magnetic Resonance Spectroscopy</other_name>
    <other_name>MRS</other_name>
    <other_name>MRS Imaging</other_name>
    <other_name>MRSI</other_name>
    <other_name>Proton Magnetic Resonance Spectroscopic Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a known diagnosis of central nervous system (CNS) malignancy, including
             metastases, with known enhancement on magnetic resonance (MR) who are otherwise
             eligible to undergo MRI

          -  Glomerular filtration rate (GFR) &gt; 30 ml/min

          -  No allergy to gadolinium

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Refusal to have an IV placed for injection

          -  Acute major illness (e.g., unstable angina, etc.) or other condition that makes
             participation unsafe, per the investigator?s judgement

          -  Total bilirubin &gt; 1.5 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 2.5 x ULN

          -  Gamma-glutamyltransferase (GGT) &gt; 2.5 x ULN

          -  Pregnant or breast-feeding

          -  Cardiovascular risk, including:

               -  Poorly controlled hypertension, defined as either systolic &gt; 170 or diastolic &gt;
                  110

               -  Congestive heart failure

               -  Myocardial infarction within the past year

               -  QT prolongation, defined as pretreatment corrected QT interval (QTc) &gt; 440 msec
                  in males or &gt; 460 msec in females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Recht</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Daniel M. Spielman</investigator_full_name>
    <investigator_title>Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

